4.95
price up icon0.00%   0.00
pre-market  Pre-market:  4.94   -0.010   -0.20%
loading
2 Seventy Bio Inc stock is traded at $4.95, with a volume of 4.06M. It is up +0.00% in the last 24 hours and up +107.11% over the past month. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
See More
Previous Close:
$4.95
Open:
$4.94
24h Volume:
4.06M
Relative Volume:
4.78
Market Cap:
$255.36M
Revenue:
$44.12M
Net Income/Loss:
$-156.25M
P/E Ratio:
-1.6124
EPS:
-3.07
Net Cash Flow:
$-154.61M
1W Performance:
+77.42%
1M Performance:
+107.11%
6M Performance:
+7.84%
1Y Performance:
+4.65%
1-Day Range:
Value
$4.94
$4.95
1-Week Range:
Value
$2.55
$4.95
52-Week Range:
Value
$2.29
$5.99

2 Seventy Bio Inc Stock (TSVT) Company Profile

Name
Name
2 Seventy Bio Inc
Name
Phone
339-499-9300
Name
Address
60 BINNEY STREET, CAMBRIDGE
Name
Employee
425
Name
Twitter
Name
Next Earnings Date
2024-12-12
Name
Latest SEC Filings
Name
TSVT's Discussions on Twitter

Compare TSVT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TSVT
2 Seventy Bio Inc
4.95 255.36M 44.12M -156.25M -154.61M -3.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
495.42 127.22B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
689.50 75.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.45 35.94B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.43 31.38B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.84 26.84B 3.32B -860.46M -1.04B -8.32

2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-06-24 Downgrade Goldman Neutral → Sell
Jan-31-24 Upgrade Leerink Partners Market Perform → Outperform
Jan-31-24 Downgrade TD Cowen Outperform → Market Perform
Oct-30-23 Downgrade Leerink Partners Outperform → Market Perform
Oct-12-23 Initiated Citigroup Buy
Sep-13-23 Downgrade Goldman Buy → Neutral
Sep-12-23 Downgrade Guggenheim Buy → Neutral
Jul-28-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-31-22 Initiated Guggenheim Buy
May-02-22 Initiated Goldman Buy
Feb-10-22 Initiated SVB Leerink Outperform
Jan-06-22 Initiated Cowen Outperform
Nov-09-21 Initiated Canaccord Genuity Buy
Nov-08-21 Initiated Morgan Stanley Overweight
Nov-08-21 Initiated Wedbush Outperform
View All

2 Seventy Bio Inc Stock (TSVT) Latest News

pulisher
01:21 AM

2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World

01:21 AM
pulisher
Mar 10, 2025

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire

Mar 10, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace

Mar 07, 2025
pulisher
Mar 06, 2025

2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com

Mar 06, 2025
pulisher
Feb 16, 2025

Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World

Feb 16, 2025
pulisher
Feb 06, 2025

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire

Feb 06, 2025
pulisher
Feb 05, 2025

Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive

Feb 05, 2025
pulisher
Jan 20, 2025

Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World

Jan 20, 2025
pulisher
Jan 04, 2025

Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Jan 04, 2025
pulisher
Dec 18, 2024

Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Dec 18, 2024
pulisher
Nov 15, 2024

Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report - Simply Wall St

Nov 15, 2024
pulisher
Nov 12, 2024

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress - Business Wire

Nov 12, 2024
pulisher
Nov 06, 2024

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results - GlobeNewswire

Nov 06, 2024

2 Seventy Bio Inc Stock (TSVT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

2 Seventy Bio Inc Stock (TSVT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Snow Jessica
See Remarks
Jan 03 '25
Sale
2.94
1,000
2,936
152,479
Snow Jessica
See Remarks
Jan 07 '25
Sale
2.64
186
491
147,179
Leschly Nick
Director
Jan 03 '25
Sale
2.94
85,978
252,423
1,234,498
Leschly Nick
Director
Jan 06 '25
Sale
2.78
892
2,478
1,233,606
Eatwell Victoria
Chief Financial Officer
Jan 03 '25
Sale
2.94
1,013
2,974
339,076
Eatwell Victoria
Chief Financial Officer
Jan 06 '25
Sale
2.78
97
270
338,979
Baird William D III
President and CEO
Jan 03 '25
Sale
2.94
31,718
93,121
862,889
Baird William D III
President and CEO
Jan 06 '25
Sale
2.78
763
2,120
862,126
Snow Jessica
See Remarks
Dec 13 '24
Sale
3.23
2,287
7,393
153,479
$35.01
price up icon 3.70%
$307.09
price up icon 0.88%
$32.85
price up icon 1.20%
$19.91
price up icon 7.62%
$100.31
price up icon 1.95%
biotechnology ONC
$249.84
price up icon 1.68%
Cap:     |  Volume (24h):